AstraZeneca CEO hails NHS drug price deal but keeps pause on £200m UK investment
Pascal Soriot suggests UK-US agreement will not be enough to revive plan to expand Cambridge siteBusiness live – latest updatesThe boss of Britain’s biggest pharmaceutical company has said the government’s...
By Julia Kollewe · The Guardian World
Pascal Soriot suggests UK-US agreement will not be enough to revive plan to expand Cambridge site Business live – latest updates The boss of Britain’s biggest pharmaceutical company has said the government’s recent drug pricing deal is a “very positive step” but is unlikely to unfreeze a paused £200m investment in Cambridge. AstraZeneca’s chief executive Pascal Soriot suggested that a UK-US deal on NHS pricing agreed in December would not be “sufficient” to restart the project to build a research site in the east of England, which was paused in September. Continue reading...